KALA PHARMACEUTICALS INC's ticker is KALA and the CUSIP is 483119103. A total of 126 filers reported holding KALA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 1.35 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $3,000 | -25.0% | 12,270 | 0.0% | 0.00% | – |
| Q2 2022 | $4,000 | -77.8% | 12,270 | -3.7% | 0.00% | – |
| Q1 2022 | $18,000 | -10.0% | 12,745 | -19.1% | 0.00% | – |
| Q4 2021 | $20,000 | -45.9% | 15,745 | +10.5% | 0.00% | – |
| Q3 2021 | $37,000 | -35.1% | 14,245 | +32.3% | 0.00% | – |
| Q2 2021 | $57,000 | +216.7% | 10,770 | +310.3% | 0.00% | – |
| Q1 2021 | $18,000 | +50.0% | 2,625 | +64.1% | 0.00% | – |
| Q3 2020 | $12,000 | – | 1,600 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CAXTON CORP | 1,142,360 | $7,745,000 | 4.83% |
| RA Capital Management | 10,874,613 | $73,730,000 | 1.03% |
| Mesirow Financial Investment Management, Inc. | 43,431 | $294,462,000 | 0.93% |
| Parkman Healthcare Partners LLC | 272,445 | $1,847,000 | 0.47% |
| Samsara BioCapital, LLC | 601,162 | $4,076,000 | 0.41% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 102,198 | $693,000 | 0.40% |
| Eventide Asset Management | 3,450,000 | $23,391,000 | 0.36% |
| Orbimed Advisors | 5,465,030 | $37,053,000 | 0.32% |
| Vivo Capital, LLC | 786,883 | $5,335,000 | 0.24% |
| Knights of Columbus Asset Advisors LLC | 169,429 | $1,149,000 | 0.12% |